Ozmosi | TXR-1210 Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

TXR-1210

Alternative Names: txr-1210, txr 1210, txr1210
Clinical Status: Active
Latest Update: 2022-08-30
Latest Update Note: Clinical Trial Update

Product Description

TXR-1210 is a first-in-class small molecule from twoXAR pharmaceuticals for the treatment of chronic kidney disease. (Sourced from: https://ariapharmaceuticals.com/safety-of-two-novel-chronic-kidney-disease-treatment-candidates/)

Mechanisms of Action: IL1 Regulator, Pyroptosis Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Aria
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 0: Kidney Diseases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events

Date

Type

Title

08/30/2022

News Article

 Aria Pharmaceuticals Advances Pipeline with Six Provisional US Patents Filed Across Three Diseases

03/04/2021

News Article

 twoXAR Pharmaceuticals Presents Preclinical Data Showing Significant Efficacy and Safety of Two Novel Chronic Kidney Disease Treatment Candidates

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions